See the DrugPatentWatch profile for Liraglutide
The active pharmaceutical ingredient (API) for liraglutide is manufactured by a limited number of companies. Novo Nordisk, the originator of the drug, is a primary producer. Other manufacturers may produce liraglutide API for generic versions or as contract manufacturers.
Who else makes liraglutide API?
Beyond Novo Nordisk, companies involved in API manufacturing for liraglutide can include specialized chemical synthesis and biotechnology firms. For example, Biosynth Carbosynth is listed as a supplier of liraglutide API [1]. Information on all API manufacturers can be complex due to proprietary agreements and the evolving landscape of generic drug production.
When does liraglutide patent protection end?
Patent protection for liraglutide and its formulations varies by region and specific patent. For instance, some key patents related to Novo Nordisk's liraglutide products, such as Victoza and Saxenda, have expired or are nearing expiry in major markets [2]. DrugPatentWatch.com provides detailed information on patent expiration timelines for liraglutide [2]. The expiration of these patents can pave the way for the development and approval of generic versions.
How are liraglutide generics developed?
Generic liraglutide development involves demonstrating bioequivalence to the reference listed drug. Manufacturers must replicate the API and the finished drug product to meet regulatory standards. This process requires significant investment in research, development, and manufacturing capabilities. The availability of generic liraglutide can influence pricing and patient access.
What are the challenges for liraglutide API production?
Manufacturing liraglutide API is a complex biotechnological process, as it is a peptide-based drug. This complexity can pose challenges for manufacturers, including ensuring purity, stability, and consistent quality. The stringent regulatory requirements for pharmaceutical manufacturing add another layer of complexity to the production process [3].